Brad Rice
Education
Ph.D., economics, and M.A., political economy, Boston University; B.A., economics, University of Florida
Summary of Experience
Dr. Rice is an economist who serves as an expert and consultant in complex litigation, government investigations, and arbitration matters across health care, sports, technology, finance, and other regulated industries. His work spans a broad range of alleged conduct, including False Claims Act violations, antitrust and competition issues, consumer data privacy, insider trading, trade secret misappropriation, breach of contract, and valuation disputes. Dr. Rice has been retained as an expert witness and has provided sworn testimony in both federal civil and criminal proceedings. He has also supported expert engagements in matters involving liability, causation, class certification, and damages. His analyses frequently rely on large‑scale administrative and transactional datasets and employ advanced econometric, statistical, and financial techniques, including causal inference methods, merger simulation, valuation modeling, and lost profits analysis. Dr. Rice develops interactive and scenario‑based models used by counsel in real‑time litigation settings and has presented findings to multiple US Attorney’s Offices. In addition to his litigation practice, Dr. Rice provides analyses and consults to health care organizations on research and strategic decision making. He has published in peer‑reviewed journals and presented research at academic and professional conferences. Previously, Dr. Rice taught undergraduate courses in econometrics, health economics, industrial organization, and regulatory economics as adjunct faculty in the department of economics at Harvard University and as a lecturer in the department of economics at Boston University.
-
Prescription Opioid Utilization Patterns, and Associated Outcomes, among Privately-Insured Patients Prescribed Opioids to Manage Pain Associated with Osteoarthritis
Current Medical Research and Opinion, 2023
2023Schepman P, Rice JB, Beck CG, White A, Robinson RL, Thakkar S, Fernan C, Emir B, Silverman S
-
Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis
Advances in Therapy, 2023
2023Hayes K, Niewoehner J, Rice JB, Downes N, Hagopian E, Ma I, Wan GJ
-
Telehealth Growth Trends Highlight Emerging Risks
Law360, June 14, 2021
2021Rotenstein L, Rice B, Kumcu J
-
Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome
Current Medical Research and Opinion, 2021
2021Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ
-
Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States
Ocular Immunology and Inflammation, 2020
2020Albini TA, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
Neurology and Therapy, 2020
2020Rice JB, Panaccio MP, White A, Simes M, Billmyer E, Downes N, Niewoehner J, Wan GJ
-
Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases
Clinical Therapeutics, 2019
2019Nelson WW, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Albini TA
-
Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis
Clinical Chemistry and Laboratory Medicine. May 1 2018
2018Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
-
Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population
Journal of Medical Economics. 2018 Sep;21(9):846-852
2018Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population
Current Medical Research and Opinion. 2018 Aug;34(8):1519-1527
2018Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW
-
The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review
Current Medical Research and Opinion. 2018 Dec;34(12):2095-2103
2018 -
Economic burden of sarcoidosis in a commercially-insured population in the United States
Journal of Medical Economics. Oct 2017;20(10):1048-1055
2017Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ
-
High-cost sarcoidosis patients in the United States: Patient characteristics and patterns of health care resource utilization
Journal of Managed Care and Specialty Pharmacy. 2017;23(12):1261-1269a
2017 -
The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States
Current Medical Research and Opinion. Aug 2017;33(8):1473-1480
2017Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K
-
Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review
Clinical Therapeutics. Nov 2017;39(11):2216-2229
2017 -
Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis
Critical Care Medicine. Dec 21 2017
2017Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P
-
Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population
Journal of Medical Economics, 2016 07; 19(7): 649-654
2016Rice BJ, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.
-
Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers
J Med Econ. 2015 Mar 19:1-18
2015Rice B, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB
-
The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals
Pain Med. 2015 Apr 30. doi: 10.1111/pme.12768
2015Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
-
Sources of prescription opioids among diagnosed opioid abusers
Curr Med Res Opin. 2015 Apr;31(4):779-84
2015Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R
-
Burden of diabetic foot ulcers for medicare and private insurers
Diabetes Care. 2014 Mar; 37(3):651-8
2014Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB
-
The economic burden of diagnosed opioid abuse among commercially insured individuals
Postgrad Med. 2014 Jul;126(4):53-8
2014Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R
-
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data
Appl Health Econ Health Policy. 2014 Aug;12(4):435-46
2014Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R
-
A model to identify patients at risk for prescription opioid abuse, dependence, and misuse
Pain Med. 2012 Sep; 13(9):1162-73
2012Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL
-
A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees
Health Econ. 2009 Mar; 18(3):275-90
2009Rice JB, Kasper JD, Pezzin LE